EMBARGOED FOR RELEASE: 3 P.M. (CT), MONDAY, OCTOBER 14, 2013
Media Advisory: To contact author Elizabeth V. Asztalos, M.D., call Sybil Edmonds at 416-480-4040 or email firstname.lastname@example.org.
CHICAGO – Multiple courses of prenatal corticosteroids, compared with a single course, taken by pregnant women to help prevent preterm birth was associated with no increase or decrease in the risk of death or disability for their children at age 5, according to a study published by JAMA Pediatrics, a JAMA Network publication.
Preterm birth (between 24 and 33 weeks) is a significant health problem and a single course of prenatal (also known as antenatal) corticosteroid therapy is recommended for women at risk of preterm birth. Questions remain about whether additional courses of corticosteroids might be safe and beneficial, the authors write in the study background.
Elizabeth V. Asztalos, M.D., of the Sunnybrook Health Sciences Centre, Toronto, Canada, and colleagues examined the effects of single vs. multiple courses of corticosteroids on the risk of death and neurodevelopmental disability (including cerebral palsy, blindness, deafness or abnormal attention or behavior) in children of mothers who participated in the Multiple Courses of Antenatal Corticosteroids for Preterm Birth Study (MACS). The follow-up study included more than 1,700 mothers and their children.
Study findings indicate no difference in the risk of death or neurodevelopmental disability: 217 of 871 children (24.9 percent) in the multiple-courses group vs. 210 of the 848 children (24.8 percent) in the single-course group.
“Multiple courses, compared with a single course, of antenatal corticosteroid therapy did not increase or decrease the risk of death or disability at 5 years of age. Because of a lack of strong conclusive evidence of short-term or long-term benefits, it remains our opinion that multiple courses should not be recommended in women with ongoing risk of preterm birth,” the study concludes.
(JAMA Pediatr. Published online October 14, 2013. doi:10.1001/jamapediatrics.2013.2764. Available pre-embargo to the media at http://media.jamanetwork.com.)
Editor’s Note: Please see the articles for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
# # #
For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email email@example.com.